Literature DB >> 1746003

A kinetic model of the circulatory regulation of tissue plasminogen activator.

W L Chandler1.   

Abstract

A computer simulation was developed to study the regulation of active tissue plasminogen activator (t-PA) levels in plasma by kinetically modeling t-PA secretion, t-PA inhibition by plasminogen activator inhibitor type 1 (PAI-1), and hepatic clearance of t-PA, PAI-1 and t-PA/PAI-1 complex throughout a simplified human circulatory system. The model indicates that as the active PAI-1 concentration increases, the percent of t-PA in the active form decreases exponentially. Further, the reaction between t-PA and PAI-1 substantially reduces the half-lives of both active factors. By adjusting the t-PA and PAI-1 secretion rates to provide the best fit between simulated and measured circadian variations in t-PA, PAI-1 and complex, the model predicts that the diurnal rhythm in active t-PA levels is principally due to changes in the rate of PAI-1 secretion and not to variations in the t-PA secretion rate. In conclusion, the model predicts that PAI-1 is an important regulator of the concentration, half-life and circadian variation of active t-PA.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1746003

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  9 in total

1.  The economic production of anti-microbial factor from human promyelocytes in low serum containing medium under chemostat cultivation.

Authors:  Y N Kim; H G Kim; S K Lim; K Y Park; J S Park; H Murakami; H Y Lee
Journal:  Cytotechnology       Date:  1995-01       Impact factor: 2.058

Review 2.  Nonalcoholic Fatty Liver Disease-Evidence for a Thrombophilic State?

Authors:  Margaret Spinosa; Jonathan G Stine
Journal:  Curr Pharm Des       Date:  2020       Impact factor: 3.116

3.  No association of the plasminogen activator inhibitor-1 promoter 4G/5G polymorphism with inhibitor level during basal transcription in vitro.

Authors:  Mei Zhan; Yuling Zhou; Zhong Chao Han
Journal:  Int J Hematol       Date:  2004-05       Impact factor: 2.490

4.  Short term effects of GnRH agonists on plasma fibrinolytic balance in patients with advanced prostate cancer.

Authors:  Mehmet Agirbasli; Oytun A Baykan; Ali Tekin; Feridun Sengor; Altug A Cincin; Muzaffer Demir; Douglas E Vaughan
Journal:  J Thromb Thrombolysis       Date:  2008-01-09       Impact factor: 2.300

5.  Endothelial binding of recombinant tissue plasminogen activator: quantification in vivo using a recirculatory model.

Authors:  Michiel J Kemme; Rik C Schoemaker; Jacobus Burggraaf; Monique van der Linden; Marina Noordzij; Matthijs Moerland; Cornelis Kluft; Adam F Cohen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-02       Impact factor: 2.745

Review 6.  Functional stability of plasminogen activator inhibitor-1.

Authors:  Songul Yasar Yildiz; Pinar Kuru; Ebru Toksoy Oner; Mehmet Agirbasli
Journal:  ScientificWorldJournal       Date:  2014-10-15

7.  Link between plasminogen activator inhibitor-1 and cardiovascular risk in chronic hepatitis C after viral clearance.

Authors:  Ming-Ling Chang; Yu-Sheng Lin; Li-Heng Pao; Hsin-Chih Huang; Cheng-Tang Chiu
Journal:  Sci Rep       Date:  2017-02-13       Impact factor: 4.379

8.  Longitudinal Assessment of Cytokine Expression and Plasminogen Activation in Hantavirus Cardiopulmonary Syndrome Reveals Immune Regulatory Dysfunction in End-Stage Disease.

Authors:  Peter Simons; Yan Guo; Virginie Bondu; Susan L Tigert; Michelle Harkins; Samuel Goodfellow; Cana Tompkins; Devon Chabot-Richards; Xuexian O Yang; Laura Gonzalez Bosc; Steven Bradfute; Daniel A Lawrence; Tione Buranda
Journal:  Viruses       Date:  2021-08-12       Impact factor: 5.048

9.  Herba Artemisiae Capillaris Extract Prevents the Development of Streptozotocin-Induced Diabetic Nephropathy of Rat.

Authors:  Jianan Geng; Xiaoyan Yu; Chunyu Liu; Chengbo Sun; Menghuan Guo; Zhen Li; Yingli Jin; Yinggang Zou; Jinghua Yu
Journal:  Evid Based Complement Alternat Med       Date:  2018-02-14       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.